Valuation: Atossa Therapeutics, Inc.

Market Cap 24.35M 21.75M 20.23M 18.4M 34.74M 2.36B 34.89M 243M 95.4M 1.2B 91.44M 89.44M 3.86B P/E 2026 *
-0.65x
P/E 2027 * -0.88x
Enterprise Value 24.35M 21.75M 20.23M 18.4M 34.74M 2.36B 34.89M 243M 95.4M 1.2B 91.44M 89.44M 3.86B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+0.83%
1 week+4.27%
Current month+25.13%
1 month+1.67%
3 months+3.39%
6 months-51.00%
Current year-72.43%
1 week 2.12
Extreme 2.12
2.74
1 month 1.82
Extreme 1.82
2.74
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
17.25
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
48.3
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/26 A
Ensisheim Partners LLC
OtherCompany 0 0% -
5/12/26 A Free

Director

10,000 0.1161%
5/12/26 A Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+4.27%-86.21%-76.43% 24.35M
-2.59%-5.70%+39.83%+82.45% 70.61B
+3.23%-10.67%+4.87%+55.97% 51.01B
+1.56%+1.17%+5.15%+33.38% 48.1B
+0.39%+0.65%+28.02%+30.24% 42.78B
+0.87%-8.17%+298.53%+645.03% 40.67B
+1.24%-1.01%+5.56%+105.14% 40.3B
-2.13%-1.64%+7.51%+50.31% 30.59B
-0.46%-1.28%+31.47%+19.93% 28.16B
+5.32%+0.06%-7.20%-11.30% 24.36B
Average +0.83%-1.96%+32.75%+93.47% 37.66B
Weighted average by Cap. +0.56%-2.94%+47.30%+116.50%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.52M -29.32M -26.67M -50.36M -3.42B -50.58M -353M -138M -1.74B -133M -130M -5.59B -38.03M -33.96M -31.59M -28.74M -54.26M -3.68B -54.49M -380M -149M -1.88B -143M -140M -6.02B
Net Debt - -
Projected Income Statement - Annual - Atossa Therapeutics, Inc.
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
09/10/26 $2.440 +0.83% 265,612
08/10/26 $2.420 -1.63% 101,012
07/10/26 $2.460 +0.41% 19,070
06/10/26 $2.450 0.00% 54,625
05/10/26 $2.450 +4.70% 53,315
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Atossa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.440USD
Average target price
19.00USD
Spread / Average Target
+678.69%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atossa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATOS Stock